Anuh Pharma Limited

rs,

Date: 22nd August, 2025 To, The Manager (Listing) BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 BSE Scrip Code: 506260 To, Listing Compliance Department

₹186.48 crore

nancial Performance Overview‐ During the quarter under review, we achieved an Operating Revenue of ₹186.48 crores, which represents a 35% growth year‐on‐ year compared to ₹137.91 crores in the same quarter of las

35%

ng the quarter under review, we achieved an Operating Revenue of ₹186.48 crores, which represents a 35% growth year‐on‐ year compared to ₹137.91 crores in the same quarter of last year. This strong reven

₹137.91 crore

ved an Operating Revenue of ₹186.48 crores, which represents a 35% growth year‐on‐ year compared to ₹137.91 crores in the same quarter of last year. This strong revenue growth reflects our continued efforts in exp

₹30.73 crore

hancing market penetration, and strengthening our product portfolio. Our Operating Profit stood at ₹30.73 crores, almost flat compared to the previous year’s ₹31.15 crores, reflecting a stable operating perform

₹31.15 crore

ortfolio. Our Operating Profit stood at ₹30.73 crores, almost flat compared to the previous year’s ₹31.15 crores, reflecting a stable operating performance despite input cost pressures. Profitability Metrics‐

₹13.68 crore

performance despite input cost pressures. Profitability Metrics‐ EBITDA for the quarter stood at ₹13.68 crores, with margins at 7.34%, compared to 10.36% in Q1 of last year. PBT was ₹10.95 crores, compared to

7.34%

pressures. Profitability Metrics‐ EBITDA for the quarter stood at ₹13.68 crores, with margins at 7.34%, compared to 10.36% in Q1 of last year. PBT was ₹10.95 crores, compared to ₹12.27 crores in the sam

10.36%

ability Metrics‐ EBITDA for the quarter stood at ₹13.68 crores, with margins at 7.34%, compared to 10.36% in Q1 of last year. PBT was ₹10.95 crores, compared to ₹12.27 crores in the same quarter last year.

₹10.95 crore

arter stood at ₹13.68 crores, with margins at 7.34%, compared to 10.36% in Q1 of last year. PBT was ₹10.95 crores, compared to ₹12.27 crores in the same quarter last year. PAT came in at ₹8.30 crores, versus ₹9.5

₹12.27 crore

s, with margins at 7.34%, compared to 10.36% in Q1 of last year. PBT was ₹10.95 crores, compared to ₹12.27 crores in the same quarter last year. PAT came in at ₹8.30 crores, versus ₹9.51 crores in the previous ye

₹8.30 crore

ear. PBT was ₹10.95 crores, compared to ₹12.27 crores in the same quarter last year. PAT came in at ₹8.30 crores, versus ₹9.51 crores in the previous year, showing a decline of 12.7%. Reported EPS was ₹1.66, com

“Servicing Society for better tomorrow to Donated Chhatrapati Shikshan for Mandal of Building Toilet Block for about 3200 student of the School Service Funds to Churchgate for for challenged Sports Donated Lions Promoting specially children's to Indian Donated Foundation (Project Aashayein) education children Development for underprivileged the to 36 CSR ….”

“Servicing Society for better tomorrow Donated to Late Shri Manilal Kantilal Charitable sonawala providing Trust education and accommodation to the needy girls for Donated to Indian Development Foundation (Project Dignity) for providing menstrual hygiene kits and sanitary pads for the needy girl children's Donated to Greensole Foundation for providing recycled footwear's and masks for the needy children's 37 Thank You For specific queries please feel free to contact; Mr.”

Market leadership

1

Market leadership

Erythromycin salts Pyrazinamide Sulfadoxine Ambroxol HCL Gliclazide Clobetasol Propionate Betamethasone Dipropionate Competitive Advantage • Regulatory approvals • Environmental health and Safety Compliance (Audited an approved by Multinational companies). • Well diversified sourcing with backward integration in key products. • Surplus capacity available • Financially strong • Strong R&D capabilities 17 Product List Macrolides Higher Macrloides 1. Erythromycin 11,12 Carbonate 1. Azithromycin 2. Erythromycin Base Anti TB 3. Erythromycin Estolate 1. Pyrazinamide 4. Erythromycin Propionate 2. Isoniazid 5. Erythromycin Ethyl Succinate Anti Bacterial Anti Asthamatics 1. Acebrophylline Anti Diabetic 1. Gliclazide 2. Vildagliptin 3. Dapagliflozin 6. Erythromycin Phosphate 1. Chloramphenicol Antibiotic 7. Erythromycin Stearate 2. Chloramphenicol Palmitate 1. Sulfadimethoxine Expectorant 1.Ambroxol HCL 2.Acefylline Piperazine Quinolones 1.Moxifloxacin Anti Malarial 1. Sulfadoxine 2. Pyrimethami